Gargiulo, Luigi
Ibba, Luciano http://orcid.org/0000-0002-7876-4866
Malagoli, Piergiorgio
Burroni, Anna G.
Chiricozzi, Andrea
Dapavo, Paolo
Ferrucci, Silvia M.
Gola, Massimo
Napolitano, Maddalena
Ortoncelli, Michela
Rossi, Maria T.
Sciarrone, Claudio
Costanzo, Antonio
Narcisi, Alessandra
Article History
Received: 19 January 2024
Accepted: 28 February 2024
First Online: 21 March 2024
Declarations
:
: Luigi Gargiulo has been a consultant for Almirall. Luciano Ibba has been a consultant for Almirall. Piergiorgio Malagoli has been a speaker for AbbVie, Lilly, Novartis, Janssen-Cilag, Celgene, Leopharma, and Almirall. Andrea Chiricozzi has served as advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Leo Pharma, Lilly, Janssen, Novartis, Pfzer and Sanof Genzyme. Paolo Dapavo has been a speaker for Novartis, Abbvie, Sanofi, UCB, Janssen, Lilly, and LeoPharma. Silvia M. Ferrucci has been principal investigator in clinical trials for ABBVIE, Almirall, Galderma, Leo Pharma, Sanofi, Amgen, Novartis, Bayer and received honoraria for lectures for Novartis and Menarini. Maddalena Napolitano acted as speaker, consultant and/or advisory board member for Abbvie, Eli Lilly, Leo Pharma, Novartis, and Sanofi. Michela Ortoncelli has served as a consultant and/or speaker for AbbVie, LEO Pharma, Novartis and Sanofi. Maria T. Rossi has received personal fee for advisory board meeting from Sanofi, Abbvie, Novartis, and Cantabria. Antonio Costanzo has served as an advisory board member, consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB-Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim. Anna G. Burroni, Massimo Gola and Claudio Sciarrone have nothing to declare.
: Institutional review board approval was exempted for this study as its procedures did not include human subjects and did not deviate from good clinical practice. All the involved dermatologists gave their approval for the study to be published. All the dermatologists who were part of the consensus were involved in the writing and/or revision of the manuscript. All the dermatologists who participated in the consensus were aware of the objective of the study, and they all knew that the manuscript will be published. The participants gave written informed consent.